Profil:
Ryvu Therapeutics SARyvu Therapeutics posts PLN 30.1 mln EBITDA loss and 32.8 mln EBIT loss in Q2 2024
Listed biotech firm Ryvu Therapeutics posted an EBITDA loss of PLN 30.1 million (EUR 7 mln) and an EBIT loss of PLN 32.8 million (EUR 7.7 mln) in the second quarter of 2024. Excluding the incentive programme and the valuation of shares in NodThera, the second quarter loss from operations was PLN 31.9 million (EUR 7.45 mln) and EBITDA loss was PLN 29.2 million (EUR 6.82 mln), the company said in a report.
The net loss in the second quarter of 2024 was PLN 30.4 million (EUR 7.1 mln). The net loss excluding the incentive programme is PLN 29.4 million (EUR 6.9 mln).
Total revenue from operations amounted to PLN 23 million (EUR 5.4 mln) against PLN 25.5 million (EUR 6 mln) in the prior year period.
The PAP Biznes consensus was for a revenue of PLN 22.5 million (EUR 5.3 mln), EBITDA loss of PLN 26.1 million (EUR 6.1 mln), EBIT loss of PLN 29.1 million (EUR 6.8 mln) and net loss of PLN 27.1 million (EUR 6.3 mln).
In the second quarter of 2023, the company posted approximately PLN 15.3 million (EUR 3.6 mln) in revenue, PLN 28.9 million (EUR 6.8 mln) in EBITDA loss, PLN 31.6 million (EUR 7.4 mln) in EBIT loss and PLN 28.5 million (EUR 6.6 mln) in net loss.
alk/ han/ ao/